Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $44.67.
Several equities analysts have recently commented on the stock. Stifel Nicolaus boosted their price target on shares of Trupanion from $30.00 to $40.00 and gave the company a “hold” rating in a report on Monday, September 23rd. Piper Sandler upped their target price on Trupanion from $45.00 to $57.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Northland Securities lifted their price target on Trupanion from $45.00 to $50.00 and gave the company a “market perform” rating in a report on Thursday, October 31st. Finally, Bank of America increased their price objective on Trupanion from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, September 20th.
View Our Latest Report on Trupanion
Trupanion Stock Performance
Trupanion (NASDAQ:TRUP – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The financial services provider reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. Trupanion had a negative net margin of 1.08% and a negative return on equity of 4.36%. The business had revenue of $327.50 million for the quarter, compared to analyst estimates of $321.79 million. During the same quarter in the previous year, the business earned ($0.10) earnings per share. The firm’s revenue was up 14.6% compared to the same quarter last year. As a group, equities analysts predict that Trupanion will post -0.23 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Murray B. Low sold 2,000 shares of Trupanion stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.67, for a total value of $105,340.00. Following the transaction, the director now directly owns 131,513 shares in the company, valued at approximately $6,926,789.71. The trade was a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Fawwad Qureshi sold 9,867 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $53.08, for a total value of $523,740.36. The disclosure for this sale can be found here. Insiders sold 28,405 shares of company stock valued at $1,512,482 over the last 90 days. 5.50% of the stock is currently owned by company insiders.
Institutional Trading of Trupanion
A number of institutional investors and hedge funds have recently modified their holdings of TRUP. Quest Partners LLC acquired a new position in Trupanion in the third quarter worth about $37,000. Wilmington Savings Fund Society FSB bought a new position in shares of Trupanion during the 3rd quarter worth approximately $54,000. GAMMA Investing LLC boosted its stake in Trupanion by 70.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,442 shares of the financial services provider’s stock valued at $61,000 after buying an additional 596 shares in the last quarter. Headlands Technologies LLC acquired a new position in Trupanion during the second quarter worth $162,000. Finally, Entropy Technologies LP acquired a new stake in shares of Trupanion in the 3rd quarter valued at $202,000.
Trupanion Company Profile
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Recommended Stories
- Five stocks we like better than Trupanion
- 3 Fintech Stocks With Good 2021 Prospects
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- The How and Why of Investing in Gold Stocks
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.